Disease relevance of Cytembena

• Seventeen patients with stages III and IV alkylating agent-resistant ovarian carcinomas were treated with cytembena, which was given in doses of 200 mg/m2 twice daily for 5 consecutive days every 5 weeks [1].
• The frequency of abnormal metaphases and chromosomal breaks after Cytembena treatment was low; nonetheless, the indicated dose-effect relationship was found in all the rodents used [2].
• Twenty-two patients were given progressively increasing doses of Cytembena to determine toxicity patterns and to establish a dosage which produces definite but clinically tolerable toxicity when the drug is given by intravenous injections in a 5-day intensive course [3].
• Thirty women with histologically proven advanced ovarian or breast cancer were treated with cytembena [4].
• Improvement, particularly relief of pain from skeletal metastases, was observed in 16 of the patients; an additional seven patients had stable disease while treated with cytembena [4].

High impact information on Cytembena

• Description of a permeable eukaryotic cell system to study agents affecting DNA synthesis: demonstration that cytembena is a direct inhibitor of replicative DNA synthesis [5].
• Cytembena, sodium cis-beta-4-methoxybenzoyl-beta-bromoacrylate, also inhibited DNA synthesis in the permeable cells; this demonstrated that this agent functioned as a direct inhibitor of the DNA replication complex [5].
• Effect of sodium cis-beta-4-methoxybenzoyl-beta-bromacrylate (Cytembena) on HeLa cell kinetics [6].
• Evidence for the nonenzymatic and irreversible binding of cytembena to rat liver microsomes in vitro [7].
• Relationship between experimental results in mammals and man. II. Cytogenetic analysis of bone-marrow cells after treatment of cytembena and cyclophosphamide- cytembena combination [2].

Chemical compound and disease context of Cytembena

• The rodents appeared to be 3--4 times more sensitive to the induction of chromosomal breaks and abnormal metaphases than man, after a dose of 20 mg Cytembena and 20 mg cyclophosphamide/kg body wt [2].
• Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer [8].

Biological context of Cytembena

• The treatment of HeLa cells with various concentrations of sodium beta-4-methoxybenzoyl-beta-bromacrylate (Cytembena) results in inhibition of growth and modification of cell cycle distribution [6].
• Pharmacokinetics of Cytembena in chronic renal impairment [9].
• The decline in renal Cytembena clearance is slower than that of glomerular filtration rate due, probably, to a lowered tubular reabsorption of Cytembena in residual nephrons [9].

Anatomical context of Cytembena

• Coronary artery disease and impaired renal function should be contraindications to Cytembena therapy, and caution should be employed in the patients with significant impairment of liver function [3].
• This change in tubular resorption of Cytembena is related to a decrease of the fractional reabsorption of sodium in residual nephrons [9].
• In patients with malignant tumors, changes in the blood count and morphological changes in the nucleoli in peripheral-blood lymphocytes were studied during treatment with Cytembena, Cyclophosphamide, or combinations of both drugs [10].
• The checkings were done in patients with advanced stages of malignant tumors processes with primary localization in the digestive tract, receiving cytostatic treatment with Cytembena Spofa and Cyclophosphamide Germed [11].

Analytical, diagnostic and therapeutic context of Cytembena

• The frequency of chromosomal breaks was 2--3 times higher in rodents in comparison with man, after treatment with a dose of 20 mg Cytembena/kg body wt [2].
• Two of 22 patients, both with far-advanced carcinoma and previous chemotherapy failures, showed a favorable objective response to Cytembena therapy [3].

References